A 2-Stage Adaptive Design, Phase 2 Study to Evaluate the Efficacy, Safety and Tolerability of CBL-514 Injection for Reducing Abdominal and Thigh Subcutaneous Fat (Stage 1)
Latest Information Update: 01 Apr 2024
At a glance
- Drugs CBL-514 (Primary)
- Indications Obesity
- Focus Adverse reactions
- Sponsors Caliway Biopharmaceuticals
- 17 Mar 2022 Status changed from recruiting to completed.
- 26 Jul 2021 Planned End Date changed from 1 Jun 2021 to 1 Oct 2021.
- 26 Jul 2021 Planned primary completion date changed from 1 Jun 2021 to 1 Oct 2021.